Novartis' del-desiran misses HARBOR trial's primary endpoint, adding to pelacarsen miss and CAR-T deaths; shares sink 10%.
In the wake of its high-profile setback in heart disease late last week, Novartis really needed a win.
It didn’t get one.
The Swiss pharma …
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
The HARBOR study failure is Novartis's second major late-stage trial setback in days and its third pipeline blow in a week
Shares of Novartis tanked on Tuesday after results from its del-desiran drug trial disappointed investors.
Novartis' pelacarsen fails Lp(a)HORIZON, the third major CV outcomes trial miss in two months, as Amgen, Lilly and others push…
The failure of “del-desiran,” which Novartis got through a $12 billion acquisition, could raise questions about the company’s…
(Bloomberg) -- Novartis AG suffered its third clinical-trial setback in a week after a treatment for a rare muscle-wasting…
Shares in the market heavyweight plummeted by over 10% at one point during early trading on Tuesday following the failure of a…
Novartis RNA drug falls short in rare muscle disease study
